Plant-based Covid-19 vac­cine de­vel­op­er Med­ica­go shut down this week with lit­tle fan­fare. And its two sub­sidiaries, Med­ica­go R&D and Med­ica­go USA, are al­so clos­ing their doors, ac­cord­ing to a com­pa­ny news re­lease.
QUEBEC CITY--(BUSINESS WIRE)--Medicago today announced the publication of the results from the Phase 3 study of COVIFENZ®, COVID-19 vaccine (plant-based virus-like particles [VLP], recombinant, adjuvanted), in the New England Journal of Medicine (NEJM). The Phase 3 trial studied the two-dose regimen of COVIFENZ® given 21 days apart versus placebo in over 24,000 subjects aged 18 and above. Common side effects in the vaccine group included injection site pain, headache, fatigue, fever, muscle aches, and chills.
Canada’s Medicago scored a regulatory first after Health Canada approved its plant-based COVID-19 vaccine Covifenz that has been paired with GlaxoSmithKline’s pandemic adjuvant as a preventative treatment against the SARS-CoV-2 virus in individuals 18 to 64 years of age.
QUEBEC CITY--(BUSINESS WIRE)--Medicago, a biopharmaceutical company headquartered in Quebec City, is pleased to announce submission of the positive Phase 3 data for regulatory review by Health Canada as part of the New Drug Submission for COVID (NDS-CV) rolling review for Medicago’s COVID-19 vaccine candidate combined with GSK’s pandemic adjuvant. Medicago is seeking review and approval for the vaccine candidate for indication in healthy adults, aged 18 years and above.
Medicago, a biopharmaceutical company headquartered in Quebec City, and nGlaxoSmithKline plc (GSK) announce positive efficacy and safety results nfrom the global Phase 3 placebo-controlled efficacy study of Medicago's nplant-based COVID-19 vaccine candidate in combination with GSK's npandemic adjuvant, conducted in over 24,000 subjects (adults 18 years nand above) across six countries.
Medicago will initiate a study investigating its virus-like particle n(VLP) Covid-19 vaccine as a booster dose in January, medical officer nBrian Ward says. The trial will recruit in the range of 1,000 nparticipants who previously received Medicago’s vaccine or the most ncommon authorised vaccines in the US and Canada, he adds.
Canadian drug developer Medicago’s plant-based COVID-19 vaccine candidate, enhanced by GlaxoSmithKline’s booster, was 75.3 per cent effective against the Delta variant of the virus in a late stage study, the two companies said on Tuesday.
Medicago and GlaxoSmithKline have presented interim phase 2 data on their adjuvanted COVID-19 vaccine candidate. The results suggest the plant-derived jab CoVLP+AS03 is somewhat differentiated from other vaccines through the mixed cellular response it triggers.
QUEBEC CITY & LONDON--(BUSINESS WIRE)--Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) are pleased to announce the start of Phase 3 clinical testing of Medicago’s plant-derived COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant, as part of the ongoing Phase 2/3 study. Medicago received approval from Canadian and US regulatory authorities to proceed with enrollment of healthy adults in the Phase 3 portion of the trial based on positive interim Phase 2 results. In parallel, Medicago has also initiated a feasibility study of a vaccine candidate to address the emerging COVID-19 variants.